-
Edgewise Therapeutics Announces Completion of the EDG-7500 CIRRUS-HCM Phase 2 Parts B and C and Favorable Interim Safety Results from the Ongoing Part D Study in Hypertrophic Cardiomyopathy
24 Dec 2025 14:40 GMT
… impaired cardiac relaxation associated with hypertrophic cardiomyopathy (HCM) without impacting … abnormal heart rhythms, and sudden cardiac death. Individuals with HCM can become … -part-d-study-in-hypertrophic-cardiomyopathy-302649113.html
SOURCE Edgewise …
-
<![CDATA[Aficamten Receives FDA Approval for Obstructive Hypertrophic Cardiomyopathy]]>
22 Dec 2025 20:45 GMT
… with obstructive hypertrophic cardiomyopathy (oHCM), … symptomatic obstructive hypertrophic cardiomyopathy to improve … -Symptomatic-Obstructive-Hypertrophic-Cardiomyopathy-to-Improve … with symptomatic obstructive hypertrophic cardiomyopathy (SEQUOIA-HCM …
-
<![CDATA[FDA Approves Aficamten for Obstructive Hypertrophic Cardiomyopathy]]>
22 Dec 2025 19:15 GMT
… with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).1 … symptomatic obstructive hypertrophic cardiomyopathy to improve … -Symptomatic-Obstructive-Hypertrophic-Cardiomyopathy-to-Improve … for symptomatic obstructive hypertrophic cardiomyopathy. N Engl …
-
FDA Approves Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy
21 Dec 2025 14:55 GMT
… for adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional … Maron, M.D., Director, Hypertrophic Cardiomyopathy Center, Lahey Hospital and … Founder and CEO of the Hypertrophic Cardiomyopathy Association (HCMA). “For far …
-
FDA Approves Cytokinetics' MYQORZO For Treatment Of Obstructive Hypertrophic Cardiomyopathy
20 Dec 2025 09:05 GMT
… of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). The therapy is indicated …
-
Cytokinetics Announces FDA Approval of MYQORZO™ (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms
19 Dec 2025 21:00 GMT
… extension clinical study. About Hypertrophic Cardiomyopathy Hypertrophic cardiomyopathy (HCM) is a … the leading causes of sudden cardiac death in younger people … . Risk factors of sudden cardiac death in hypertrophic cardiomyopathy. Current Opinion in …
-
<![CDATA[FDA Approves Aficamten (Myqorzo) for Symptomatic Obstructive Hypertrophic Cardiomyopathy]]>
19 Dec 2025 21:56 GMT
… of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve … Martin Maron, MD, Director, Hypertrophic Cardiomyopathy Center, Lahey Hospital and Medical … Founder and CEO of the Hypertrophic Cardiomyopathy Association.1 “For far …
-
Letter to Editor: Why Winter Is Hard on the Kashmiri Heart
24 Dec 2025 16:13 GMT
… in emergencies.
Heart attacks, strokes, sudden cardiac deaths and hospital admissions for heart …
-
Cytokinetics’ Moment of Truth: Can Aficamten Take On BMS in Hypertrophic Cardiomyopathy?
19 Dec 2025 14:59 GMT
… for the company’s obstructive hypertrophic cardiomyopathy (oHCM) molecule aficamten is December …
-
GLP-1 Receptor Agonists Linked to Lower All-Cause Mortality in Hypertrophic Cardiomyopathy: AHJ, December 2025 Study Reveals New Cardiovascular Benefits
19 Dec 2025 10:07 GMT
… , arrhythmias, heart failure, and sudden cardiac death. Patients who also have type … worldwide. Adults diagnosed with hypertrophic cardiomyopathy and type 2 diabetes were … GLP-1 Receptor Agonists in Hypertrophic Cardiomyopathy: Mortality Benefit with Complex …
About
© 1995-2025